Blood: The efficacy of Daremu mono-anti-to-take-to-natamine-borazonandand and dexamethasone to treat newly diagnosed transplantable multiple myeloma

Self-stem cell transplantation (ASCT) after treatment with Nalaamine, boronitami and Dexameton (RVd) is the standard first-line therapy for newly diagnosed patients with multiple myeloma (NDMM) for transplantationthis study evaluated the effect of RVd combined with Daremu monoantigen (D) therapy in NDMM patients who met asCT conditionsA total of 207 patients were randomly grouped with 1:1 and received RVd-D induction (4 courses), ASCT, RVd-D consolidation (2 courses) and Amine-D maintenance (26 courses)in the main endpoint analysis, at the end of asCT consolidation therapy, the strict full response rate (sCR) of patients receiving D-RVd treatment was significantly better than that of patients receiving RV treatment (42.4 percent vs 32.0 percent; advantage ratio 1.57; 95% CI 0.87-2.82; one-sided P-0.068) and met the pre-set single-sided alpha of 0.10the mitigation level continued to increase with the extension of follow-up time (median time 22.1 months), and the sCR rate of D-RVd increased compared to RVd (62.6% vs 45.4% ;PIn the D-RVd group and RVd group, there were 4 (3.8%) and 7 (6.8%) patients with progression, with no progression survival rate of 95.8% (D-RVd) and 89.8% (RVd) in 24 months, respectivelyLevel 3/4 hematological adverse events in the D-RVd group were more commonThe D-RVd group had more infections, but the 3/4 infection rate was similarThe median yield of CD34 plus cells in the D-RVd group and the RVd group was 8.2 to 106/kg and 9.4 to 106/kg, respectivelyIn addition, there was no difference in the median time between neutrophils and platelet implants between the two groups, Daremu monoantigen combined With RVd induction and consolidation can improve the remission depth of NDMM patients who meet the transplant conditions without causing new safety problems